title: Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
abstract: Gelatinous marrow transformation (GMT) is an unusual pathological manifestation of progressive malignant diseases and severe malnutrition states. GMT has been associated with various accelerated hematological malignancies, but has never been described in patients with chronic myelogenous leukemia (CML) treated with imatinib mesylate (IM), a novel tyrosine kinase inhibitor. Herein we report 2 patients with stable chronic phase CML who developed GMT during the course of treatment with IM. A comprehensive review of the relevant published data, several possible mechanisms and therapeutic alternatives are suggested.
authors: Institute of Hematology, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel. ramr@clalit.org.il
authors: Ron
authors: R
authors: Ram
authors: Anat
authors: A
authors: Gafter-Gvili
authors: Elimelech
authors: E
authors: Okon
authors: Idit
authors: I
authors: Pazgal
authors: Ofer
authors: O
authors: Shpilberg
authors: Pia
authors: P
authors: Raanani
mesh_terms: D000328:Adult; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology*; D001856:Bone Marrow Examination; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate